Memorial Sloan Kettering Cancer Center’s Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value drug development.
Bach said while it’s a complex effort, the goal is to pay as little as possible to pharmaceutical companies to “incentivize high-value innovation and development.”
“It’s hard to know in advance how much you need to pay a company to do a certain type of work and take on certain types of risks,” he said. “But it’s still the right first-order question.”
To read the full interivew, click here.